Clinical investigators discuss available data guiding the management of gynecologic cancers. CME information and select publications here .
Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here .
Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. CME information and select publications here .
Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here .
Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here .
Clinical investigators discuss available data guiding the management of prostate cancers. CME information and select publications here .
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. CME information and select publications here .
Clinical investigators discuss available data guiding the management of biliary tract cancers. CME information and select publications here .
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here .
Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. CME information and select publications here .
Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. CME information and select publications here .
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here .
Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. CME information and select publications here .
Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here .
Dr Kathleen Moore, Dr Ritu Salani, Dr Shannon Westin and moderator Dr Angeles Alvarez Secord share their perspectives and summarize recently presented data from the SGO 2025 annual meeting guiding the management of ovarian cancer. CME information and select publications here .
Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here .
Clinical investigators discuss available data guiding the management of sarcoma and other connective tissue neoplasms. CME information and select publications here .
Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. CME information and select publications here .
Clinical investigators discuss available data guiding the management of chronic lymphocytic leukemia. CME information and select publications here .
Clinical investigators discuss available data guiding the management of neuroendocrine tumors. CME information and select publications here .
Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here .
Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer. CME information and select publications here .
Dr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. CME information and select publications here .
Drs Kathleen N Moore and Alessandro D Santin and moderator Dr David M O’Malley summarize and share their perspectives on data guiding the management of HER2-positive gynecologic cancers that were presented at the Society of Gynecologic Oncology 2025 annual meeting. CME information and select publications here .
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer. CME information and select publications here .
Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma. NCPD information and select publications here .
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here .
Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. CME information and select publications here .
Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.
Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma. CME information and select public...
